Related Experiment Video
Updated: Jul 9, 2026
07:43
Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis
Published on: February 8, 2017
26.6K
Sarcoma brain metastases: Tertiary cancer center experience
Hazim Sameer Ababneh1, Baha'eddin Muhsen1, Ahmad Salah Fares2
1Division of Neurosurgery, Department of Surgery, King Hussein Cancer Center, Amman, Jordan.
Journal of Cancer Research and Therapeutics
|February 22, 2024
Summary
Brain metastasis from bone and soft tissue sarcomas is rare, with Ewing sarcoma being a common subtype. This study assessed its characteristics and outcomes, finding a dismal prognosis.
Area of Science:
- Oncology
- Neurosurgery
- Medical Research
Background:
- Brain metastasis (BM) from bone and soft tissue sarcomas (STS) is exceptionally rare.
- Optimal therapeutic strategies for STS BM are not well-defined due to limited data.
Purpose of the Study:
- To determine the prevalence, disease characteristics, and outcomes of BM in patients with STS.
- To evaluate prognostic factors influencing overall survival (OS) in this patient cohort.
Main Methods:
- Retrospective chart review of 1,548 bone and STS patients treated between 2007 and 2020.
- Kaplan-Meier method for survival estimation and univariate analysis for prognostic factors.
Main Results:
- BM occurred in 1.1% of patients, with Ewing sarcoma (ES) being the most frequent subtype (28%).
- Median overall survival (OS) after BM diagnosis was 4.0 months, with no identified factors influencing OS.
Conclusions:
- Sarcoma BM is a rare event associated with a poor prognosis.
- Ewing sarcoma is a significant histological subtype contributing to BM in STS.
Related Concept Videos
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...